Innate Pharma S.A. (IPHA) Key Metrics
IPHA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · eurosIPHA returns How much profit the business earns on the capital it uses.
Return on assets−22.0 pts
−56.6%
2025 · hover or tap a bar for each year
20162025
Asset turnover−63.6%
0.03
2025 · hover or tap a bar for each year
20162025
IPHA financial health Debt, liquidity and how easily interest is covered.
Net debt+€38.0M
−€11.7M
2025 · hover or tap a bar for each year
20162025
Current ratio−51.0%
1.27
2025 · hover or tap a bar for each year
20162025
Interest coverage
-121.4
2025 · hover or tap a bar for each year
20162025
Debt / assets+29.0%
0.36
2025 · hover or tap a bar for each year
20162025
IPHA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−90 days
606 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+81.3 pts
84.4%
2025 · hover or tap a bar for each year
20162025
IPHA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IPHA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IPHA key metrics in euros
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −162.9% | −14.3% | −71.9% | −40.1% | −34.3% | −10.8% | 2.4% | −56.2% | 16.0% |
| Return on invested capital (ROIC) | — | — | — | — | −136.7% | 4.2% | −198.8% | — | — | — |
| Return on assets (ROA) | −56.6% | −34.6% | −4.0% | −24.4% | −18.4% | −18.1% | −4.9% | 0.9% | −18.0% | 4.3% |
| Return on tangible assets | −78.4% | −44.5% | −4.3% | −28.2% | −23.6% | −24.5% | −6.8% | 0.8% | −23.2% | 4.6% |
| Free cash flow margin | — | −57.7% | −67.3% | −35.2% | −493.6% | −90.4% | −44.2% | −42.5% | −165.8% | −82.3% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | −10.67 | — | −2.92 |
| Financial health | ||||||||||
| Total debt | €22.6M | €31.0M | €39.9M | €42.3M | €44.3M | €19.1M | €18.7M | €4.5M | €5.9M | €5.3M |
| Cash & short-term investments | €34.3M | €80.8M | €92.5M | €101.5M | €119.8M | €151.6M | €218.9M | €167.5M | €116.1M | €197.7M |
| Net debt | −€11.7M | −€49.8M | −€52.6M | −€59.2M | −€75.6M | −€132.6M | −€200.1M | −€163.0M | −€110.2M | −€192.4M |
| Debt / equity | — | 3.51 | 0.77 | 0.78 | 0.41 | 0.12 | 0.09 | 0.03 | 0.07 | 0.06 |
| Debt / assets | 0.36 | 0.28 | 0.23 | 0.20 | 0.17 | 0.06 | 0.05 | 0.01 | 0.02 | 0.02 |
| Net debt / EBITDA | — | — | — | — | — | −2.29 | −11.06 | −12.99 | — | −17.76 |
| Current ratio | 1.27 | 2.60 | 3.73 | 3.38 | 1.73 | 3.81 | 1.95 | 1.62 | 1.86 | 3.01 |
| Quick ratio | 1.27 | 2.60 | 3.82 | 3.38 | 1.79 | 3.74 | 1.90 | 1.62 | 1.78 | 3.00 |
| Interest coverage | -121.4 | -91.1 | -19.8 | -199.4 | -153.3 | 3.2 | -117.9 | 50.5 | -353.8 | 61.1 |
| Working capital | €10.1M | €52.8M | €108.4M | €98.5M | €58.4M | €127.8M | €115.8M | €122.9M | €63.6M | €153.6M |
| Invested capital | −€33.4M | −€40.9M | −€662,000 | −€5.1M | €31.9M | €23.4M | €17.3M | €4.2M | −€24.3M | −€106.2M |
| Tangible asset value | −€21.7M | €8.8M | €42.5M | €52.6M | €63.2M | €109.7M | €120.4M | €82.7M | €39.8M | €77.1M |
| Net current asset value | −€37.7M | −€16.5M | €15.7M | −€13.9M | −€21.8M | €21.9M | €53.7M | €35.7M | −€31.5M | €34.7M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 |
| Share buybacks (net) | — | — | — | — | — | — | €0 | €0 | €0 | €0 |
| Dividend payout ratio | — | — | — | — | — | — | — | 0.0% | — | 0.0% |
| Capex / revenue | 84.4% | 3.1% | 4.5% | 1.9% | 11.0% | 16.2% | 94.8% | 1.8% | 18.5% | 16.7% |
| Capex / operating cash flow | — | — | — | — | — | — | 187.3% | — | — | — |
| Capex / depreciation | 0.46 | 0.20 | 0.46 | 0.02 | 0.29 | 0.20 | 3.96 | 0.19 | 1.37 | 2.88 |
| Stock-based compensation / revenue | 152.7% | 31.2% | 8.2% | 7.4% | 21.6% | 3.5% | 5.5% | 3.4% | 30.1% | 1.8% |
| R&D / revenue | 1,565.1% | 411.9% | 107.9% | 89.6% | 388.1% | 71.2% | 2.3% | 87.1% | 205.3% | 86.6% |
| SG&A / revenue | 394.7% | 94.5% | 22.0% | 24.2% | 132.0% | 26.6% | 71.9% | 22.7% | 48.0% | 15.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 605.9 | 696.0 | 174.5 | 15.2 | 195.7 | 37.0 | 395.4 | 369.4 | 227.3 | 115.4 |
| Days of inventory on hand | — | — | -11.0 | -17.5 | -6.5 | 32.6 | 22.6 | 16.6 | 18.6 | 3.0 |
| Days payables outstanding | — | 57.9 | 72.4 | 100.3 | 137.7 | 178.7 | 228.4 | 127.4 | 96.9 | 90.9 |
| Cash conversion cycle (days) | — | 638.1 | 91.1 | -102.6 | 51.5 | -109.1 | 189.7 | 258.7 | 149.0 | 27.5 |
| Receivables turnover | 0.60 | 0.52 | 2.09 | 24.03 | 1.87 | 9.87 | 0.92 | 0.99 | 1.61 | 3.16 |
| Payables turnover | 0.00 | 6.31 | 5.04 | 3.64 | 2.65 | 2.04 | 1.60 | 2.87 | 3.77 | 4.02 |
| Inventory turnover | — | — | — | — | — | 11.19 | 16.13 | 21.98 | 19.59 | 122.95 |
| Asset turnover | 0.03 | 0.09 | 0.27 | 0.24 | 0.04 | 0.20 | 0.16 | 0.23 | 0.12 | 0.19 |
| Average receivables | €4.6M | €24.1M | €24.8M | €2.4M | €6.5M | €7.1M | €74.7M | €80.9M | €20.3M | €17.8M |
| Average payables | €11.5M | €8.2M | €11.1M | €14.2M | €17.7M | €24.3M | €28.3M | €24.3M | €17.8M | €12.1M |
| Average inventory | — | — | −€1.7M | −€2.5M | −€832,000 | €4.4M | €2.8M | €3.2M | €3.4M | €395,500 |
| Intangibles / total assets | 0.0% | 0.0% | 0.2% | 0.7% | 16.5% | 15.1% | 24.2% | 18.7% | 18.1% | 3.2% |
Computed from IPHA's annual financial statements (latest annual report filed April 1, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in euros; data from EODHD. Averages use the opening and closing balance of each year.
IPHA valuation and financial ratios
It ended the year with €22.6 million of debt and €34.3 million in cash and short-term investments, a net cash position of €11.7 million.
See the IPHA income statement, the IPHA chart for price history, or the IPHA stock overview for the latest quote and news.
IPHA key metrics FAQ
How much debt does Innate Pharma have?
Innate Pharma had total debt of €22.6 million at the end of fiscal 2025 and more cash than debt.
What is Innate Pharma's current ratio?
Innate Pharma's current ratio was 1.27 at the end of fiscal 2025: current assets were 1.27 times current liabilities.